Story by Abigirl Tembo, Health Editor
ZIMBABWE is set to become one of the first African nations to introduce the long-acting HIV prevention drug Lenacapavir, after authorities approved an expedited early rollout aimed at reducing new infections and easing pressure on the country’s health system.
The breakthrough medication, administered only twice a year, will be deployed under an early-introduction programme designed to generate real-world evidence before nationwide expansion. The approach will help health workers assess uptake, adherence and community response while strengthening planning for wider distribution.
Health and Child Care Minister, Dr Douglas Mombeshora, told journalists in Harare on Thursday that the Medicines Control Authority of Zimbabwe (MCAZ) authorised Lenacapavir on 22 November after a rapid 23-day review. The first 3 000 doses are expected to arrive in January, with designated facilities and trained staff ready to commence the phased rollout.
He noted that the drug, which offers more than 99 percent effectiveness when taken correctly, is expected to benefit adolescent girls, young women, key populations, mobile workers and pregnant and breastfeeding women; groups that continue to face high exposure to HIV.
Dr Mombeshora also said that twice-yearly dosing will help address persistent challenges linked to daily oral prevention, including adherence difficulties, stigma and the burden of frequent clinic visits.
However, he cautioned that Lenacapavir must not be viewed as a substitute for responsible sexual behaviour.
All HIV prevention services in Zimbabwe will remain free of charge.
Zimbabwe continues to be recognised globally for its strong and impactful HIV response and health officials say the early introduction of Lenacapavir signals the country’s commitment to adopting cutting-edge science to sustain progress and reduce new infections.
